Addex Therapeutics Ltd

Symbol: ADXN

NASDAQ

25.57

USD

Market price today

  • -159.0856

    P/E Ratio

  • -7.3709

    PEG Ratio

  • 37.61M

    MRK Cap

  • 0.00%

    DIV Yield

Addex Therapeutics Ltd (ADXN) Financial Statements

On the chart you can see the default numbers in dynamics for Addex Therapeutics Ltd (ADXN). Companys revenue shows the average of 3.407 M which is 2.830 % gowth. The average gross profit for the whole period is -0.576 M which is 13.775 %. The average gross profit ratio is -0.974 %. The net income growth for the company last year performance is 0.355 % which equals -0.504 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Addex Therapeutics Ltd, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.633. In the realm of current assets, ADXN clocks in at 7.829 in the reporting currency. A significant portion of these assets, precisely 6.96, is held in cash and short-term investments. This segment shows a change of -0.661% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0.087 in the reporting currency. This figure signifies a year_over_year change of -0.226%. Shareholder value, as depicted by the total shareholder equity, is valued at 4.913 in the reporting currency. The year over year change in this aspect is -0.710%.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

balance-sheet.row.cash-and-short-term-investments

24.5720.518.8
31.6
41.7
2.6
1.4
2.6
2
2.9
15.3
36.1
63.8
76.6
119.5
140
40.9

balance-sheet.row.short-term-investments

0.02000.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

1.910.60.30.1
0.1
0.3
0.3
0.2
0.1
0.1
0.8
1
0
0
0
0
0
0

balance-sheet.row.inventory

0-871.600.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

2.77871.91.10.5
0.7
0.2
0.2
0
0
0.1
0.2
0.8
2
2.7
1.8
3.1
3.6
1.3

balance-sheet.row.total-current-assets

29.187.821.919.5
32.4
42.2
3.1
1.7
2.8
2.1
3.9
17
38.1
66.5
78.4
122.6
143.7
42.3

balance-sheet.row.property-plant-equipment-net

1.320.40.50.6
0.6
0
0
0
0
0
0.2
2.1
4
6.7
9.6
9
4.9
3.7

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0.1
0.1
0
0.1
0.2
0.2
0.2
0.1

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0.1
0.1
0
0.1
0.2
0.2
0.2
0.1

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.220.10.10.1
0.1
0.1
0
0
0.1
1.8
1.7
2.5
1.6
1
0.4
0.5
0.6
0.4

balance-sheet.row.total-non-current-assets

1.540.50.60.7
0.6
0.1
0
0
0.1
1.9
2
4.7
5.5
7.8
10.2
9.7
5.7
4.1

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

30.718.322.520.2
33
42.2
3.1
1.7
2.9
4
5.9
21.7
43.6
74.3
88.6
132.3
149.4
46.4

balance-sheet.row.account-payables

3.861.31.81
2.2
1.1
0.4
0.7
0.2
0.6
0.6
0.7
0
0
0
0
2.6
1.8

balance-sheet.row.short-term-debt

0.920.30.30.3
0.4
0
0
0
0.1
0
0
0
0
0
0
0
0
0.1

balance-sheet.row.tax-payables

000.20.2
0.1
0
0
0
0.1
0
0
0.3
0
0
0
0
0.4
0.2

balance-sheet.row.long-term-debt-total

0.270.10.20.3
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

6.341.72.11.5
2
1
0.6
0.6
0.8
0.8
1.8
3.9
8.7
9.3
10.9
13.3
6.7
1.9

balance-sheet.row.total-non-current-liabilities

0.540.11.52
1.8
0.6
0.2
0.2
0.2
0.1
0.5
0.8
1.1
0.6
0.1
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

1.190.40.50.6
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0.1

balance-sheet.row.total-liab

11.663.45.65.6
7.5
3
1.7
1.5
1.2
1.7
2.9
5.4
9.8
9.9
11
13.3
9.3
4.1

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

5.11.249.332.8
32.8
28.6
13.4
11.6
11
10
9.8
8.6
7.7
6.3
5.7
5.7
5.7
3.9

balance-sheet.row.retained-earnings

-1414.64-349.9-329.1-313.7
-300.8
-286.1
-284.4
-281.1
-278
-273.8
-272
-256.1
-229.1
-197.9
-164.3
-121.6
-99.5
-64.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

115.6725.824.48.6
7.1
10.3
7.5
6.8
6.6
6.1
5.5
6
-17.5
-15.4
-13.8
0
0
0

balance-sheet.row.other-total-stockholders-equity

1312.92327.9272.3286.9
286.4
286.5
264.8
263
262.1
260
259.7
257.7
272.7
271.4
250
234.8
233.9
102.8

balance-sheet.row.total-stockholders-equity

19.054.916.914.6
25.5
39.2
1.3
0.2
1.7
2.3
3
16.3
33.8
64.4
77.6
119
140.1
42.3

balance-sheet.row.total-liabilities-and-stockholders-equity

30.718.322.520.2
33
42.2
3.1
1.7
2.9
4
5.9
21.7
43.6
74.3
88.6
132.3
149.4
46.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

19.054.916.914.6
25.5
39.2
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

30.71---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0.02000.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

1.190.40.50.6
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0.1

balance-sheet.row.net-debt

-23.29-6.6-20-18.1
-31
-41.7
-2.6
-1.4
-2.6
-2
-2.9
-15.3
-36.1
-63.8
-76.6
-119.5
-140
-40.8

Cash Flow Statement

The financial landscape of Addex Therapeutics Ltd has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.115. The company recently extended its share capital by issuing 1.68, marking a difference of -97.659 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to 2972.000 in the reporting currency. This is a shift of -1.098 from the previous year. In the same period, the company recorded 0.32, 0, and -0.29, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -0.31 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 2.33, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

cash-flows.row.net-income

-11.35-20.8-15.4-12.9
-14.8
-1.6
-3.3
-3.1
-4.2
-1.8
-14.5
-27
-31.1
-33.6
-42.7
-22.1
-35.1
-20.5

cash-flows.row.depreciation-and-amortization

0.30.30.30.4
0.3
0
0
0
0
0.1
0.7
2.1
2.9
2.9
2.8
2
1.8
2.5

cash-flows.row.deferred-income-tax

-0.010-0.20
0.1
0
0
0
0.9
-0.3
-0.6
0.1
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

2.093.71.21.2
1.7
2.3
0.8
0.2
0.4
0.3
0.2
0.6
0
0
0
0
0.6
0.5

cash-flows.row.change-in-working-capital

-1.750.2-0.8-1.8
2.7
0.7
0.3
0.2
0
-0.1
-1.5
-5.2
0.2
-2.4
-0.3
3.7
2.2
-1.7

cash-flows.row.account-receivables

0.11-0.3-0.10
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

2.040.4-0.91.5
-2.1
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

-2.04-0.40.9-1.6
2
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-1.870.4-0.7-1.8
2.7
0.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-non-cash-items

0.290.201
0.5
0.3
0
0
0.3
0
0
0
1.4
1.7
0.8
-1.5
-2.6
-0.4

cash-flows.row.net-cash-provided-by-operating-activities

-10.44000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.0100-0.1
0
0
0
0
0
0
0
-0.3
-0.2
-0.5
-4.2
-5.6
-2.7
-0.4

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0000
0
-0.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

0000
0
0
0
0
0.4
0.4
0.3
0.1
-0.6
-0.5
0.3
3.4
2.5
-0.5

cash-flows.row.net-cash-used-for-investing-activites

-0.0100-0.1
0
-0.1
0
0
0.4
0.4
0.3
-0.2
-0.8
-1
-3.9
-2.2
-0.2
-0.9

cash-flows.row.debt-repayment

-0.28-0.3-0.3-0.4
-0.3
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

5.51.7140.7
0
40.5
3.4
1.5
3.2
0.5
3.4
9.7
0
6
0.3
0
136.9
40.2

cash-flows.row.common-stock-repurchased

0.25-0.3-0.40
0
0
0
0
0
0
0
0
-0.2
-0.1
0
-0.1
-0.1
0

cash-flows.row.dividends-paid

-5.87-0.3-0.40
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

5.562.33.5-0.3
-0.2
-3.1
0
0
-0.3
0
-0.2
-0.8
0
13.8
0
0
-4.5
-0.6

cash-flows.row.net-cash-used-provided-by-financing-activities

5.153.116.40
-0.5
37.4
3.4
1.5
2.9
0.5
3.2
8.9
-0.2
19.7
0.3
-0.1
132.3
39.6

cash-flows.row.effect-of-forex-changes-on-cash

-0.38-0.20.1-0.6
-0.1
0
0
0
0
0
0
0
-0.2
-0.2
0
-0.5
0
0.1

cash-flows.row.net-change-in-cash

-5.67-13.51.8-12.8
-10.1
39.1
1.2
-1.2
0.7
-0.9
-12.3
-20.8
-27.7
-12.8
-42.9
-20.6
99.1
19.3

cash-flows.row.cash-at-end-of-period

24.48720.518.7
31.5
41.7
2.6
1.4
2.6
2
2.9
15.3
36.1
63.8
76.6
119.5
140
40.9

cash-flows.row.cash-at-beginning-of-period

30.1420.518.731.5
41.7
2.6
1.4
2.6
2
2.9
15.3
36.1
63.8
76.6
119.5
140
40.9
21.7

cash-flows.row.operating-cash-flow

-10.44-16.4-14.7-12.2
-9.5
1.8
-2.1
-2.7
-2.6
-1.8
-15.8
-29.5
-26.6
-31.3
-39.4
-17.8
-33
-19.6

cash-flows.row.capital-expenditure

-0.0100-0.1
0
0
0
0
0
0
0
-0.3
-0.2
-0.5
-4.2
-5.6
-2.7
-0.4

cash-flows.row.free-cash-flow

-10.45-16.4-14.7-12.2
-9.5
1.7
-2.1
-2.7
-2.6
-1.8
-15.8
-29.8
-26.8
-31.8
-43.6
-23.4
-35.7
-19.9

Income Statement Row

Addex Therapeutics Ltd's revenue saw a change of -0.512% compared with the previous period. The gross profit of ADXN is reported to be -13.2. The company's operating expenses are 21.94, showing a change of 19.108% from the last year. The expenses for depreciation and amortization are 0.32, which is a -0.002% change from the last accounting period. Operating expenses are reported to be 21.94, which shows a 19.108% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.323% year-over-year growth. The operating income is -20.52, which shows a 0.323% change when compared to the previous year. The change in the net income is 0.355%. The net income for the last year was -20.8.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

income-statement-row.row.total-revenue

2.051.42.93.6
2.8
6
0
0
0
0.1
0.1
0
2.8
2
4.1
26.8
0.5
4.7

income-statement-row.row.cost-of-revenue

18.214.612.810.4
0.2
0.1
0
0
0
0.1
0.1
1.3
28
0
0
0
0
0

income-statement-row.row.gross-profit

-16.15-13.2-9.9-6.8
2.5
5.9
0
0
0
0
0
-1.3
-25.2
2
4.1
26.8
0.5
4.7

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

8.04---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

5.26---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-1.0200.40.3
0.6
0.4
0.2
0.8
0.3
0
5.8
9.4
-0.9
-2
0
-0.1
25.9
16

income-statement-row.row.operating-expenses

13.1521.918.415.9
17.4
7.5
3.2
3.1
2.6
1.8
14.5
27
5.8
35.6
47.6
51.7
38.1
25.8

income-statement-row.row.cost-and-expenses

13.1521.918.415.9
17.4
7.5
3.2
3.1
2.6
1.8
14.5
27
33.8
35.6
47.6
51.7
38.1
25.8

income-statement-row.row.interest-income

0.08000
0
-0.1
0
0
0
0
0
0
0.1
0.1
0.4
3.3
2.6
0.2

income-statement-row.row.interest-expense

0.0200.10.1
0.1
0.2
0
0
0.2
0
0
0
0.2
0.1
0
0.5
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.27-0.30.2-0.6
0.1
-0.2
0
0
-1.4
0
0
0
-0.2
0
85.7
2.8
2.5
0.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-1.0200.40.3
0.6
0.4
0.2
0.8
0.3
0
5.8
9.4
-0.9
-2
0
-0.1
25.9
16

income-statement-row.row.total-operating-expenses

-0.27-0.30.2-0.6
0.1
-0.2
0
0
-1.4
0
0
0
-0.2
0
85.7
2.8
2.5
0.4

income-statement-row.row.interest-expense

0.0200.10.1
0.1
0.2
0
0
0.2
0
0
0
0.2
0.1
0
0.5
0
0

income-statement-row.row.depreciation-and-amortization

0.350.40.40.4
0.6
0
0
0
0
0.1
0.7
2.1
2.9
2.9
2.8
2
1.8
2.5

income-statement-row.row.ebitda-caps

-10.72---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-11.1-20.5-15.5-12.2
-14.8
-1.4
-3.2
-3.1
-3.9
-1.8
-14.5
-27
-31
-33.6
-43.1
-24.9
-37.6
-20.9

income-statement-row.row.income-before-tax

-11.35-20.8-15.4-12.9
-14.8
-1.6
-3.3
-3.1
-4.2
-1.8
-14.5
-26.6
-31.1
-33.6
42.7
-22.1
-35.1
-20.5

income-statement-row.row.income-tax-expense

0.01000
0
0
0
0
0
0
0
0
0.1
0.1
171.1
3.3
2.5
0.3

income-statement-row.row.net-income

-11.35-20.8-15.4-12.9
-14.8
-1.6
-3.3
-3.1
-4.2
-1.8
-14.5
-26.6
-31.1
-33.6
-42.7
-22.1
-35.1
-20.5

Frequently Asked Question

What is Addex Therapeutics Ltd (ADXN) total assets?

Addex Therapeutics Ltd (ADXN) total assets is 8282050.000.

What is enterprise annual revenue?

The annual revenue is 958610.000.

What is firm profit margin?

Firm profit margin is -7.871.

What is company free cash flow?

The free cash flow is -0.135.

What is enterprise net profit margin?

The net profit margin is -5.532.

What is firm total revenue?

The total revenue is -5.408.

What is Addex Therapeutics Ltd (ADXN) net profit (net income)?

The net profit (net income) is -20804213.000.

What is firm total debt?

The total debt is 373135.000.

What is operating expences number?

The operating expences are 21942645.000.

What is company cash figure?

Enretprise cash is 4754107.000.